BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 5, 2026
Home » Authors » Tamra Sami

Articles by Tamra Sami

ANDHealth bridging data divide in Australia's digital health ecosystem

May 9, 2018
By Tamra Sami

Starpharma carves out regional revenue-sharing deal with Mundipharma for Vivagel BV

May 9, 2018
By Tamra Sami
PERTH, Australia – Melbourne-based Starpharma Holdings Ltd. has entered a sales and marketing deal with Mundipharma International Ltd., which gives Mundipharma sales and marketing rights to Vivagel BV for bacterial vaginosis (BV) in Asia, the Middle East, Africa and the majority of Latin America.
Read More

Australia's Sirtex gets late, unsolicited counteroffer from China's Cdh Investments

May 8, 2018
By Tamra Sami

Starpharma carves out regional revenue-sharing deal with Mundipharma for Vivagel BV

May 7, 2018
By Tamra Sami
PERTH, Australia – Melbourne-based Starpharma Holdings Ltd. has entered a sales and marketing deal with Mundipharma International Ltd., which gives Mundipharma sales and marketing rights to Vivagel BV for bacterial vaginosis (BV) in Asia, the Middle East, Africa and the majority of Latin America.
Read More

Australia's Telix forges global partnerships to harness power of radiopharmaceuticals

May 2, 2018
By Tamra Sami
PERTH, Australia – Following its IPO on Australia's Securities Exchange in November, Aussie radiopharma company Telix Pharmaceuticals Ltd. has been building up global partnerships to prepare for a commercial build-up of its "theranostic" radiopharmaceuticals.
Read More

Australia's Telix forges global partnerships to harness power of radiopharmaceuticals

May 1, 2018
By Tamra Sami

Aussie med techs get government funding boost to bridge investment gaps

April 27, 2018
By Tamra Sami

Australia's Telix forges global partnerships to harness power of radiopharmaceuticals

April 26, 2018
By Tamra Sami
PERTH, Australia – Following its IPO on Australia's Securities Exchange in November, Aussie radiopharma company Telix Pharmaceuticals Ltd. has been building up global partnerships to prepare for a commercial build-up of its "theranostic" radiopharmaceuticals.
Read More

Aussie biotechs to benefit from strategic intervention partnering program

April 25, 2018
By Tamra Sami
PERTH, Australia – Australia's Medical Technologies and Pharmaceuticals Industry Growth Centre (MTPConnect) and Biopacific Partners have launched a new program that will work with small Australian biotechs to better prepare them for partnering with big pharma.
Read More

Avita's Recell spray-on-skin device meets primary endpoints in two pivotal trials

April 20, 2018
By Tamra Sami
Previous 1 2 … 195 196 197 198 199 200 201 202 203 … 219 220 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 2, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing